Zeng Chih-Wei
Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Int J Mol Sci. 2023 Sep 20;24(18):14349. doi: 10.3390/ijms241814349.
Spinal cord injuries (SCIs) can lead to significant neurological deficits and lifelong disability, with far-reaching physical, psychological, and economic consequences for affected individuals and their families. Current treatments for SCIs are limited in their ability to restore function, and there is a pressing need for innovative therapeutic approaches. Stem cell therapy has emerged as a promising strategy to promote the regeneration and repair of damaged neural tissue following SCIs. This review article comprehensively discusses the potential of different stem cell types, such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem/progenitor cells (NSPCs), in SCI treatment. We provide an in-depth analysis of the unique advantages and challenges associated with each stem cell type, as well as the latest advancements in the field. Furthermore, we address the critical challenges faced in stem cell therapy for SCIs, including safety concerns, ethical considerations, standardization of protocols, optimization of transplantation parameters, and the development of effective outcome measures. We also discuss the integration of novel technologies such as gene editing, biomaterials, and tissue engineering to enhance the therapeutic potential of stem cells. The article concludes by emphasizing the importance of collaborative efforts among various stakeholders in the scientific community, including researchers, clinicians, bioengineers, industry partners, and patients, to overcome these challenges and realize the full potential of stem cell therapy for SCI patients. By fostering such collaborations and advancing our understanding of stem cell biology and regenerative medicine, we can pave the way for the development of groundbreaking therapies that improve the lives of those affected by SCIs.
脊髓损伤(SCIs)可导致严重的神经功能缺损和终身残疾,给受影响的个体及其家庭带来深远的身体、心理和经济后果。目前针对脊髓损伤的治疗在恢复功能方面能力有限,因此迫切需要创新的治疗方法。干细胞疗法已成为促进脊髓损伤后受损神经组织再生和修复的一种有前景的策略。这篇综述文章全面讨论了不同类型干细胞,如胚胎干细胞(ESCs)、诱导多能干细胞(iPSCs)、间充质干细胞(MSCs)和神经干/祖细胞(NSPCs)在脊髓损伤治疗中的潜力。我们对每种干细胞类型相关的独特优势和挑战以及该领域的最新进展进行了深入分析。此外,我们探讨了脊髓损伤干细胞治疗面临的关键挑战,包括安全问题、伦理考量、方案标准化、移植参数优化以及有效结局指标的制定。我们还讨论了基因编辑、生物材料和组织工程等新技术的整合,以增强干细胞的治疗潜力。文章最后强调了科学界各利益相关者,包括研究人员、临床医生、生物工程师、行业合作伙伴和患者之间合作努力的重要性,以克服这些挑战并实现干细胞疗法对脊髓损伤患者的全部潜力。通过促进这种合作并加深我们对干细胞生物学和再生医学的理解,我们可以为开发改善脊髓损伤患者生活的突破性疗法铺平道路。